VBI VACCINES POSITIVE CLINICAL RESULTS
These shares have advanced over 300% in the past 60 days , spiking to over $1.80 in early January. This company is now on the block for a potential acquisition by a major drug company or a lucrative licensing agreement . The future is now clear . If you are willing to wait, speculators can take a small position at current levels and average down as the stock pulls back towards $1.25 support
There is resistance at the $2.00 level and any purchases above that level should be avoided . Pull your chair up to the table boys if you want to play .
VBI Vaccines (NASDAQ:VBIV) announces positive results from a second Phase 3 clinical trial, CONSTANT, evaluating lot-to-lot consistency of its Sci-B-Vac hepatitis B vaccine and comparing its safety and immunogenicity to GlaxoSmithKline’s (NYSE:GSK) Engerix-B.
The study met the primary endpoint of lot-to-lot consistency for immune response across three independent consecutively manufactured lots four weeks after the third vaccination.
Sci-B-Vac demonstrated non-inferior immunogenicity to Engerix-B at day 196, one month after the completion of the full course of vaccination with either product.
No new safety signals were observed.
Results from the first Phase 3, PROTECT, were announced in June 2019.
Marketing application submissions in the U.S., Europe and Canada will begin in Q2.
|Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision|